Genetically modified ventral forebrain/hindbrain neural progenitor cells with a triple mutation (H3.3G34R ATRX KO and TP53KO) and the addition of N-Myc in immunodeficient mice resulted in only the ventral forebrain neural precursor cell group reaching clinical endpoint, demonstrating specificity of the ventral forebrain region for tumour induction [92]. This evidence concerns the gene ATRX and neoplasm.